CBER Reorganization Aims To Fight Recruitment Challenges, Tackle Upcoming Gene Therapy Wave

A growing focus on real-world evidence and an expected infusion of user fee funding are among the reasons for the new office branches at US FDA’s biologics center.

CBER reorg
CBER added a Division of Human Capital as part of its organizational changes. • Source: Nielsen Hobbs; the Pink Sheet | Alamy image

Cell and gene therapies fueled a reorganization within the US Food and Drug Administration’s Center for Biologics Evaluation and Research, as staff prepare for an influx of applications.

CBER’s Office of Tissues and Advanced Therapies now has another branch to handle gene therapies (Gene Therapies Branch II), as...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA

More from Agency Leadership